MG
BMY.RT

Michael Gelband’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Michael Gelband’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-727,448
Closed -$502K – 2855
2020
Q4 		$502K Buy
727,448
+265,000
+57% +$564K ﹤0.01% 1249
2020
Q3 		$1.04M Buy
462,448
+462,250
+233,460% +$1.32M 0.02% 661
2020
Q2 		$1K Buy
+198
New +$714 ﹤0.01% 1724

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Michael Gelband's BMY.RT Position: Q1 2021 in Review

Michael Gelband sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 727,448 shares — an estimated $502K sold.

Michael Gelband first reported a position in BMY.RT in Q2 2020 and held it in 3 quarters. The position peaked at $1.04M in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Michael Gelband reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Michael Gelband sold 727,448 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $502K.
  • Michael Gelband first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020 and held it in 3 quarters.
  • Michael Gelband's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.04M in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on ExodusPoint Capital Management's 13F filing for Q1 2021, filed 17 May 2021.